LOGIN  |  REGISTER
Assertio
Astria Therapeutics

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

January 06, 2023 | Last Trade: US$4.90 0.02 -0.41

WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.  A corporate presentation is scheduled for 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time).

The corporate presentation given at the J.P. Morgan Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB